BRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients

Like
Comment
Favorite

BRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients

Reuters03-31

BRIEF-<a href="https://laohu8.com/S/NVO">Novo Nordisk</a> Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients

March 31 (Reuters) - Novo Nordisk A/S NOVOb.CO:

NOVO NORDISK: ANNOUNCED NEW MULTI-MONTH SUBSCRIPTION PROGRAM FOR WEGOVY FOR ELIGIBLE SELF-PAY PATIENTS
NOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM TO BE AVAILABLE FROM MAR 31 THROUGH RO, WEIGHTWATCHERS, LIFEMD
NOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM THROUGH HIMS & HERS, SESAME & OTHERS TO FOLLOW SOON
NOVO NORDISK: WEGOVY PEN ALL DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $329/MONTH, 6-MONTHS AT $299/MONTH, 12-MONTHS AT $249/MONTH
NOVO NORDISK: WEGOVY PILL 9 MG, 25 MG DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $289/MONTH, 6-MONTHS AT $269/MONTH, 12-MONTHS AT $249/MONTH

Further company coverage: [NOVOb.CO]

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2623084585?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623084585","market":"nz","top_or_hot":-1,"title":"BRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients</title></head><body><p><span>March 31 (Reuters)</span><span> - </span>Novo Nordisk A/S <span>NOVOb.CO</span>:</p><ul><li><p>NOVO NORDISK: ANNOUNCED NEW MULTI-MONTH SUBSCRIPTION PROGRAM FOR WEGOVY FOR ELIGIBLE SELF-PAY PATIENTS</p></li><li><p>NOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM TO BE AVAILABLE FROM MAR 31 THROUGH RO, WEIGHTWATCHERS, LIFEMD</p></li><li><p>NOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM THROUGH HIMS &amp; HERS, SESAME &amp; OTHERS TO FOLLOW SOON</p></li><li><p>NOVO NORDISK: WEGOVY PEN ALL DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $329/MONTH, 6-MONTHS AT $299/MONTH, 12-MONTHS AT $249/MONTH</p></li><li><p>NOVO NORDISK: WEGOVY PILL 9 MG, 25 MG DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $289/MONTH, 6-MONTHS AT $269/MONTH, 12-MONTHS AT $249/MONTH</p></li></ul><p>Further company coverage: [NOVOb.CO]</p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay Patients</title></head><body><p><span>March 31 (Reuters)</span><span> - </span>Novo Nordisk A/S <span>NOVOb.CO</span>:</p><ul><li><p>NOVO NORDISK: ANNOUNCED NEW MULTI-MONTH SUBSCRIPTION PROGRAM FOR WEGOVY FOR ELIGIBLE SELF-PAY PATIENTS</p></li><li><p>NOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM TO BE AVAILABLE FROM MAR 31 THROUGH RO, WEIGHTWATCHERS, LIFEMD</p></li><li><p>NOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM THROUGH HIMS &amp; HERS, SESAME &amp; OTHERS TO FOLLOW SOON</p></li><li><p>NOVO NORDISK: WEGOVY PEN ALL DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $329/MONTH, 6-MONTHS AT $299/MONTH, 12-MONTHS AT $249/MONTH</p></li><li><p>NOVO NORDISK: WEGOVY PILL 9 MG, 25 MG DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $289/MONTH, 6-MONTHS AT $269/MONTH, 12-MONTHS AT $249/MONTH</p></li></ul><p>Further company coverage: [NOVOb.CO]</p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4192","symbol_name":"特殊消费者服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nP8N3S5041:1","article_id":"2623084585","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623084585","pubTimestamp":1774956739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay PatientsMarch 31  - Novo Nordisk A/S NOVOb.CO:NOVO NORDISK: ANNOUNCED NEW MULTI-MONTH SUBSCRIPTION PROGRAM FOR WEGOVY FOR ELIGIBLE SELF-PAY PATIENTSNOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM TO BE AVAILABLE FROM MAR 31 THROUGH RO, WEIGHTWATCHERS, LIFEMDNOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM THROUGH HIMS & HERS, SESAME & OTHERS TO FOLLOW SOONNOVO NORDISK: WEGOVY PEN ALL DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $329/MONTH, 6-MONTHS AT $299/MONTH, 12-MONTHS AT $249/MONTHNOVO NORDISK: WEGOVY PILL 9 MG, 25 MG DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $289/MONTH, 6-MONTHS AT $269/MONTH, 12-MONTHS AT $249/MONTHFurther company coverage: [NOVOb.CO] ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4192":"特殊消费者服务","BK4167":"医疗保健技术","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMY":"Defiance Leveraged Long + Income HIMS ETF","BK4183":"个人用品","BK4196":"保健护理服务","NVO":"诺和诺德","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HMYY":"GraniteShares YieldBoost HIMS ETF"},"translate_title":"简介-诺和诺德宣布为符合条件的自费患者提供新的Wegovy多月订阅计划","themeId":"ea115adc665c74e6a4a5582f9333b9fe","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMY":0.6,"HIMZ":0.6,"NVO":1.96,"HMYY":0.6,"HIYY":0.6},"content_text":"BRIEF-Novo Nordisk Announces New Multi-Month Subscription Program For Wegovy For Eligible Self-Pay PatientsMarch 31 (Reuters) - Novo Nordisk A/S NOVOb.CO:NOVO NORDISK: ANNOUNCED NEW MULTI-MONTH SUBSCRIPTION PROGRAM FOR WEGOVY FOR ELIGIBLE SELF-PAY PATIENTSNOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM TO BE AVAILABLE FROM MAR 31 THROUGH RO, WEIGHTWATCHERS, LIFEMDNOVO NORDISK: WEGOVY SUBSCRIPTION PROGRAM THROUGH HIMS & HERS, SESAME & OTHERS TO FOLLOW SOONNOVO NORDISK: WEGOVY PEN ALL DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $329/MONTH, 6-MONTHS AT $299/MONTH, 12-MONTHS AT $249/MONTHNOVO NORDISK: WEGOVY PILL 9 MG, 25 MG DOSES SUBSCRIPTION PLANS FOR 3-MONTHS AT $289/MONTH, 6-MONTHS AT $269/MONTH, 12-MONTHS AT $249/MONTHFurther company coverage: [NOVOb.CO] ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}